Tag: clinical trials
-
Lower Drug Dose Reduces Cataract Surgery Inflammation, Pain
26 September 2014. A clinical trial of more than 500 patients shows a lower-dose formulation of a current medication reduces eye pain and inflammation among more post-surgical cataract patients than a placebo. Bausch and Lomb, a subsidiary of Valeant Pharmaceuticals in Laval, Quebec, Canada, reported today results of the late-stage clinical trial. The trial tested…
-
Safety Trial Underway for Addiction Drug Candidate
23 September 2014. A clinical trial is underway testing the safety of a new therapy designed to treat addictions and compulsive behavior by Savant HWP, a drug development company in San Carlos, California. The study is testing the compound 18-methoxycoronaridine or 18-MC, conducted in South America by a Brazilian partner company identified as Hebron Farmaceutica…
-
U.S., Canada Authorities OK Biotech Ebola Treatments
23 September 2014. Tekmira Pharmaceuticals Corp. says the U.S. Food and Drug Administration approved the company providing its experimental therapy for people with suspected or confirmed Ebola infections. The Vancouver, British Columbia biotechnology company says approval of its therapy called TKM-Ebola is part of a larger regulatory framework for the treatments worked out with FDA and…
-
Boehringer Ingelheim Licenses RNA Lung Cancer Immunotherapy
19 September 2014. The pharmaceutical company Boehringer Ingelheim is licensing from biopharmaceutical enterprise CureVac a vaccine based on RNA to generate an immune response for treating lung cancer. The deal has a total potential value to CureVac of €465 million ($US 597 million). CureVac, in Tübingen, Germany, develops vaccines and treatments based on messenger RNA,…
-
Early Clinical Trial to Test Leukemia Antibody Safety
17 September 2014. An early stage clinical trial at University of California in San Diego is testing the safety of an antibody that in lab animals decreases the number of chronic lymphocytic leukemia cells, the most common form of leukemia among adults. The study is led by UC-San Diego medical school professor Thomas Kipps, who…
-
Lilly, AstraZeneca Collaborate on Alzheimer’s Drug
16 September 2014. The pharmaceutical companies Eli Lilly and Company and AstraZeneca will jointly develop a drug to treat Alzheimer’s disease, currently in early-stage clinical trials. In the $500 million deal, Lilly is licensing research and development conducted so far by AstraZeneca, with the companies dividing up further clinical development, commercialization, and manufacturing of the…
-
Re-Analyzed Clinical Trial Data Often Draw New Conclusions
10 September 2014. Researchers at Stanford University in California, with colleagues in Canada, analyzed decades of clinical trials to find a large proportion of the small number of studies where data were re-analyzed came to different conclusions from the original authors. The team led by Stanford medical professor John Ioannidis published its findings in today’s…
-
Grant Funding Crowdsourced Multiple Sclerosis Drug Trial
8 September 2014. A grant from a National Institutes of Health agency is funding a crowdsourced clinical trial of a generic blood pressure drug to help treat multiple sclerosis. The $1.4 million grant from National Center for Advancing Translational Sciences (NCATS) is supporting an intermediate stage clinical study by Transparency Life Sciences LLC, a drug…
-
Multi-Purpose Drug Boosts Adherence After Heart Attack
3 September 2014. Researchers at Mount Sinai Hospital in New York and National Centre for Cardiovascular Research in Madrid, Spain found a pill combining three cardiovascular drugs usually prescribed separately helps heart attack patients stick to their medications better than the three drugs taken separately. The team led by Valentin Fuster, accredited to both institutions,…
-
Breakthrough Status Given Parkinson’s Psychosis Drug
2 September 2014. Acadia Pharmaceuticals says the U.S. Food and Drug Administration designated its drug candidate pimavanserin as a breakthrough therapy for the treatment of psychosis associated with Parkinson’s disease. Acadia is a biopharmaceutical company in San Diego specializing in neurological and central nervous system disorders. Pimavanserin is Acadia’s lead therapy candidate, to be offered…